Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

382 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A comparative study of neurocognitively impaired patients receiving protease inhibitor monotherapy or triple-drug antiretroviral therapy.
Estébanez M, Stella-Ascariz N, Mingorance J, Pérez-Valero I, González-Baeza A, Bayón C, Lakatos B, Borobia A, Arnalich F, Arribas JR. Estébanez M, et al. Among authors: arribas jr. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):419-23. doi: 10.1097/QAI.0000000000000337. J Acquir Immune Defic Syndr. 2014. PMID: 25197825
Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).
Pulido F, Arribas JR, Miró JM, Costa MA, González J, Rubio R, Peña JM, Torralba M, Lonca M, Lorenzo A, Cepeda C, Vázquez JJ, Gatell JM; EfaVIP Cohort Study Group. Pulido F, et al. Among authors: arribas jr. J Acquir Immune Defic Syndr. 2004 Apr 1;35(4):343-50. doi: 10.1097/00126334-200404010-00003. J Acquir Immune Defic Syndr. 2004. PMID: 15097150
Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study).
Arribas JR, Pulido F, Delgado R, Lorenzo A, Miralles P, Arranz A, González-García JJ, Cepeda C, Hervás R, Paño JR, Gaya F, Carcas A, Montes ML, Costa JR, Peña JM. Arribas JR, et al. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):280-7. doi: 10.1097/01.qai.0000180077.59159.f4. J Acquir Immune Defic Syndr. 2005. PMID: 16249701 Clinical Trial.
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Arribas JR, Pozniak AL, Gallant JE, Dejesus E, Gazzard B, Campo RE, Chen SS, McColl D, Holmes CB, Enejosa J, Toole JJ, Cheng AK. Arribas JR, et al. J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):74-8. doi: 10.1097/QAI.0b013e31815acab8. J Acquir Immune Defic Syndr. 2008. PMID: 17971715 Clinical Trial.
Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis.
Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, Pérez-Elias MJ, Iribarren JA, Rubio R, Ocampo A, Sánchez-Conde M, Knobel H, Arazo P, Sanz J, López-Aldeguer J, Montes ML, Pulido F; OK04 Study Group. Arribas JR, et al. J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):147-52. doi: 10.1097/QAI.0b013e3181a56de5. J Acquir Immune Defic Syndr. 2009. PMID: 19349870 Clinical Trial.
Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression.
Pulido F, Pérez-Valero I, Delgado R, Arranz A, Pasquau J, Portilla J, Rubio R, González-García J, Miralles P, Pérez-Elías MJ, Ocampo A, Hernando A, Estrada V, Clotet B, Podzamczer D, Arribas JR. Pulido F, et al. Among authors: arribas jr. Antivir Ther. 2009;14(2):195-201. doi: 10.1177/135965350901400210. Antivir Ther. 2009. PMID: 19430094
Protease inhibitor monotherapy.
Pérez-Valero I, Arribas JR. Pérez-Valero I, et al. Among authors: arribas jr. Curr Opin Infect Dis. 2011 Feb;24(1):7-11. doi: 10.1097/QCO.0b013e3283422cdf. Curr Opin Infect Dis. 2011. PMID: 21150592 Review.
382 results